Patients who take either Esbriet (pirfenidone, sold by Genentech) or Ofev (nintedanib, by Boehringer Ingelheim) — two…
Articles by Iqra Mumal, MSc
The presence of auto-antibodies (self-directed antibodies) known as antineutrophil cytoplasmic antibodies do not correlate with disease severity or survival in…
Patients with idiopathic pulmonary fibrosis (IPF) have, on average, only slight cognitive impairment compared to healthy people. Also, IPF patients…
Treatment with Ofev (nintedanib) offers less clinical benefit to patients with severe idiopathic pulmonary fibrosis (IPF) than to those with mild-to-moderate…
East River BioSolutions has received a $224,566 grant from the National Heart, Lung, and Blood Institute of the…
Mesenchymal stem cells derived from the bone marrow of people with idiopathic pulmonary fibrosis (IPF) perform basic cell functions, like…
Veracyte will present new results that showcase the ability of the Envisia Genomic Classifier to provide reliable data that…
The National Institutes of Health (NIH) has granted $12 million to researchers at Cedars-Sinai Medical Center to continue studying two lung diseases — idiopathic…
Astragaloside IV — a compound isolated from a traditional Chinese medicinal plant — was found to reverse epithelial–mesenchymal transition, a…
Galectin Therapeutics was issued a patent for its lead investigative therapy GR-MD-02 for the treatment of pulmonary fibrosis by the …